IA Trial Radar

Discutamos y exploremos los ensayos clínicos con Chugai Pharmaceutical como patrocinador principal o colaborador.

Puedo ayudarle a entender sus condiciones de salud, tratamientos o encontrar ensayos clínicos cercanos.
Nuestra herramienta de búsqueda solo admite inglés. Para búsquedas y discusiones en otros idiomas, use la IA Trial Radar o seleccione los filtros de condición médica y ubicación a continuación.
43 ensayos clínicos
 
Tipo de estudio
Intervencionista
×
 
Título del estudio
Estado
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A (ZEBRHA 2) NCT07416604
Aún no recluta
A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A (ZEBRHA 1) NCT07416526
Aún no recluta
Study of DONQ52 in Active Celiac Disease NCT07239336
Reclutando
A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER NCT07107490
Reclutando
Study of AUBE00 in Patients With Solid Tumors NCT07030959
Reclutando
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-2) NCT06819891
Reclutando
Estudio para evaluar la eficacia y la seguridad del tratamiento de inducción y mantenimiento con afimkibart (RO7790121) en participantes con enfermedad de Crohn de moderada a gravemente activa (SIBERITE-1) NCT06819878
Reclutando
Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC (INDUCE) NCT06793553
Reclutando
Estudio para evaluar la eficacia y la seguridad de divarasib y pembrolizumab frente a pembrolizumab y pemetrexed y carboplatino o cisplatino en participantes con cáncer de pulmón no microcítico no escamoso avanzado o metastásico con mutación KRAS G12C no tratado previamente. (Krascendo 2) NCT06793215
Reclutando
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) NCT06723106
Reclutamiento por invitación
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-1) NCT06589986
Activo, no reclutando
Estudio para evaluar la eficacia y la seguridad de divarasib frente a sotorasib o adagrasib en participantes con cáncer de pulmón no microcítico avanzado o metastásico con mutación KRAS G12C previamente tratado. (Krascendo 1) NCT06497556
Activo, no reclutando
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) NCT06371417
Reclutando
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors NCT05907980
Reclutando
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152) (SKYSCRAPER-14) NCT05904886
Activo, no reclutando
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 NCT05867121
Activo, no reclutando
A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors NCT05735366
Completado
Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial) NCT05679570
Activo, no reclutando
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis (Cielo) NCT05503264
Reclutando
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS) NCT05494619
Retirado
Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients NCT05425446
Completado
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (Meteoroid) NCT05271409
Reclutando
A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention (SAkuraBonsai) NCT05269667
TerminadoResultados publicados
A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma NCT05022927
Activo, no reclutando
A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). NCT05012618
Terminado
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis NCT04963270
TerminadoResultados publicados
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS) (COMMUTE-p) NCT04958265
Activo, no reclutando
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) (COMMUTE-a) NCT04861259
Activo, no reclutando
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion (COMINO) NCT04740931
CompletadoResultados publicados
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion (BALATON) NCT04740905
CompletadoResultados publicados
A Phase III Study of Bevacizumab and Paclitaxel in Combination with Atezolizumab As a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer (AMBITION) NCT04732598
Activo, no reclutando
A Clinical Pharmacology Study to Evaluate the Effect of GYM329 on Disuse Muscle Atrophy in Healthy Volunteer NCT04708847
Completado
Excretion Balance, PK and Metabolism of a Single Oral Dose of [14C]PCO371 NCT04649216
Completado
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). NCT04511845
Activo, no reclutando
A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors (COMMODORE 2) NCT04434092
Activo, no reclutandoResultados publicados
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors (COMMODORE 1) NCT04432584
Activo, no reclutando
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment (CONTACT-03) NCT04338269
TerminadoResultados publicados
A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With Hypoparathyroidism NCT04209179
Terminado
A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer (IMpassion050) NCT03726879
CompletadoResultados publicados
Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria (COMPOSER) NCT03157635
Activo, no reclutando
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A (HAVEN 4) NCT03020160
CompletadoResultados publicados
A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis NCT02965053
Completado
A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors (HAVEN 3) NCT02847637
CompletadoResultados publicados